OTC Monograph 'Disruption' Could Ride On PDUFA Reauthorization's Back
This article was originally published in The Tan Sheet
Executive Summary
Changing the monograph process would be "one example of where disruption can be positive," CEO Scott Melville says at CHPA's executive conference. Legislation that would be added to the PDUFA reauthorization could be the best chance for monograph reform, but will be a lengthy process.
You may also be interested in...
OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
While still awaiting the addition of OTC user fees to pending user fee authorization, and congressional approval of the overall package, FDA has developed guidelines closely tracking Sens. Isakson and Casey's OTC proposal. FDA plans a webinar to update industry on how OTC user fees would work.
OTC Monograph User Fee Goals Document Beats Authorization To Finish Line
While still awaiting the addition of OTC user fees to pending user fee authorization, and congressional approval of the overall package, FDA has developed guidelines closely tracking Sens. Isakson and Casey's OTC proposal. FDA plans a webinar to update industry on how OTC user fees would work.
OTC Hangover Remedy Safety On Tap For FDA Advisory Committees
CDER schedules an NDAC and DSRMAC joint meeting while also negotiating with industry stakeholders on a potential proposal for a user fee program to support FDA’s work on finalizing monographs or amending monographs with additional ingredients or indications.